BioNTech SE (NASDAQ:BNTX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of BioNTech SE (NASDAQ:BNTXGet Rating) have been assigned a consensus rating of “Moderate Buy” from the fourteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $243.42.

Several research analysts have recently issued reports on BNTX shares. The Goldman Sachs Group set a $209.00 price objective on BioNTech in a research note on Thursday, June 30th. TheStreet raised BioNTech from a “d+” rating to a “c-” rating in a research note on Wednesday, May 4th. Deutsche Bank Aktiengesellschaft set a $180.00 price objective on BioNTech in a research note on Friday, July 1st. SVB Leerink upped their price objective on BioNTech from $223.00 to $224.00 and gave the company an “outperform” rating in a research note on Friday, July 29th. Finally, Morgan Stanley decreased their target price on shares of BioNTech from $195.00 to $194.00 and set an “equal weight” rating for the company in a research report on Friday, July 15th.

Hedge Funds Weigh In On BioNTech

Large investors have recently bought and sold shares of the stock. KRS Capital Management LLC bought a new position in BioNTech during the 4th quarter valued at $25,000. Koshinski Asset Management Inc. bought a new position in BioNTech during the 1st quarter valued at $26,000. Covestor Ltd bought a new position in BioNTech during the 4th quarter valued at $47,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its stake in BioNTech by 66.7% during the 1st quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 250 shares of the company’s stock valued at $43,000 after acquiring an additional 100 shares in the last quarter. Finally, DeDora Capital Inc. purchased a new stake in shares of BioNTech during the 1st quarter valued at $51,000. 14.42% of the stock is currently owned by institutional investors.

BioNTech Stock Up 1.2 %

BNTX stock opened at $180.44 on Friday. The stock has a market capitalization of $43.85 billion, a P/E ratio of 3.14 and a beta of -0.08. The company has a current ratio of 5.05, a quick ratio of 4.93 and a debt-to-equity ratio of 0.01. BioNTech has a 12 month low of $117.08 and a 12 month high of $464.00. The firm has a 50-day moving average price of $154.39 and a 200-day moving average price of $157.13.

BioNTech (NASDAQ:BNTXGet Rating) last posted its earnings results on Monday, May 9th. The company reported $15.98 EPS for the quarter, topping analysts’ consensus estimates of $9.14 by $6.84. The firm had revenue of $6.37 billion during the quarter, compared to analysts’ expectations of $4.50 billion. BioNTech had a net margin of 55.13% and a return on equity of 122.24%. The business’s revenue for the quarter was up 211.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.29 earnings per share. As a group, equities research analysts anticipate that BioNTech will post 34.28 EPS for the current fiscal year.

About BioNTech

(Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.

Further Reading

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.